Dose titration of the oral potassium binder RLY5016 to maintain normal serum potassium in heart failure and chronic kidney disease patients on aldosterone antagonists

被引：0
|
作者：
Pitt, B. [1 ]
Bushinsky, D. [2 ]
Halfon, S. [3 ]
Kitzman, D. [4 ]
Lainscak, M. [5 ]
Mathur, V. [6 ]
Stasiv, Y. [3 ]
Huang, I. [3 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
[3] Relypsa, Santa Clara, CA USA
[4] Wake Forest Univ, Winston Salem, NC 27109 USA
[5] Univ Clin Golnik, Golnik, Slovenia
[6] Mathur Consulting, Woodside, CA USA
来源：
EUROPEAN HEART JOURNAL | 2011年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：789 / 789
页数：1
相关论文
共 20 条
  • [1] A MULTICENTER STUDY OF DOSE TITRATION OF THE ORAL POTASSIUM BINDER RLY5016 TO MAINTAIN NORMAL SERUM POTASSIUM IN PATIENTS WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE TREATED WITH RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS AND/OR ?-BLOCKERS
    Pitt, Bertram
    Bushinsky, David
    Halfon, Sherin
    Kitzman, Dalane
    Lainscak, Mitja
    Mathur, Vandana
    Stasiv, Yuri
    Huang, I-Zu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E301 - E301
  • [2] PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016
    Buysse, Jerry M.
    Huang, I-Zu
    Pitt, Bertram
    FUTURE CARDIOLOGY, 2012, 8 (01) : 17 - 28
  • [3] Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
    Pitt, Bertram
    Anker, Stefan D.
    Bushinsky, David A.
    Kitzman, Dalane W.
    Zannad, Faiez
    Huang, I-Zu
    EUROPEAN HEART JOURNAL, 2011, 32 (07) : 820 - 828
  • [4] Potassium supplement use may increase hospitalization without affecting mortality in chronic heart failure: Implications for use of aldosterone antagonists to maintain potassium balance in chronic heart failure
    Ahmed, Ali
    Adamopoulos, Chris
    Sui, Xuemei
    Love, Thomas E.
    CIRCULATION, 2007, 116 (16) : 766 - 766
  • [5] Serum aldosterone to potassium ratio and hyperkalemia risk in patients with chronic kidney disease
    Kim, Hyunwoo
    Ko, Ara
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [6] Serum aldosterone to potassium ratio and hyperkalemia risk in patients with chronic kidney disease
    Kim, Hyunwoo
    Ko, Ara
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2220 - I2221
  • [7] Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes
    Collins, Allan J.
    Pitt, Bertram
    Reaven, Nancy
    Funk, Susan
    McGaughey, Karen
    Wilson, Daniel
    Bushinsky, David A.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (03) : 213 - 221
  • [8] Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
    Clephas, Pascal R. D.
    Radhoe, Sumant P.
    Linssen, Gerard C. M.
    Langerveld, Jorina
    Plomp, Jacobus
    Smits, Jeroen P. P.
    Nagelsmit, Michiel J.
    Rocca, Hans-Peter Brunner-La
    Brugts, Jasper J.
    ESC HEART FAILURE, 2023, 10 (02): : 1481 - 1487
  • [9] Serum potassium levels and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
    Clephas, P. R. D.
    Radhoe, S. P.
    Linssen, G. C. M.
    Langerveld, J.
    Erol-Yilmaz, A.
    Plomp, J.
    Smits, J. P. P.
    Nagelsmit, M. J.
    Brunner-La Rocca, H. P.
    Brugts, J. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 142 - 143
  • [10] Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
    Pitt, Bertram
    Bakris, George L.
    Bushinsky, David A.
    Garza, Dahlia
    Mayo, Martha R.
    Stasiv, Yuri
    Christ-Schmidt, Heidi
    Berman, Lance
    Weir, Matthew R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) : 1057 - 1065
12